Lexicon Pharmaceuticals Inc expected to post a loss of 8 cents a share - Earnings Preview

Lexicon Pharmaceuticals

04/08/2025 13:45

Lexicon Pharmaceuticals Inc LXRX.OQ LXRX.O is expected to  show a rise in quarterly revenue when it reports  results on August 6 for the period ending June 30 2025

The The Woodlands Texas-based  company is expected to report a 195.5% increase in revenue to $4.868 million from $1.65 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Lexicon Pharmaceuticals Inc is for a loss of 8 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Lexicon Pharmaceuticals Inc is $1.20, about 10.8% above its last closing price of $1.07

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.10
-0.10
-0.07
Beat
28.2
Dec. 31 2025
-0.13
-0.13
-0.09
Beat
29.3
Sep. 30 2024
-0.17
-0.16
-0.18
Missed
-9.4​
Jun. 30 2024
-0.19
-0.19
-0.17
Beat
9.9
​​Mar. 31 2024
-0.20
-0.20
-0.20
Met
-1.3
Dec. 31 2023
-0.22
-0.22
-0.20
Beat
7.9​
Sep. 30 2023
-0.21
-0.21
-0.21
Met
2.2
Jun. 30 2023
-0.17
-0.17
-0.22
Missed
-25.9

This summary was machine generated August 4 at 12:45 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)